Does Medicaid Pay for Ozempic in 2026? State-by-State Coverage Rules Explained

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• 47 states cover Ozempic through Medicaid for type 2 diabetes with prior authorization, but only 12 states cover it for weight loss as of April 2026
• Your specific coverage depends on your state's formulary tier, diagnosis code, BMI documentation, and whether you've tried metformin or other first-line therapies
• Medicaid patients cannot use the Novo Nordisk savings card, making state formulary status the only path to affordable access
• When Medicaid denies coverage, compounded semaglutide ($179 to $279 monthly) costs less than Ozempic's $940+ cash price

Direct answer (40-60 words)

Most state Medicaid programs cover Ozempic for type 2 diabetes in 2026, but require prior authorization proving medical necessity. Coverage for weight loss remains limited to 12 states. Copays range from $0 to $8 per fill for eligible patients. Medicaid beneficiaries cannot use manufacturer copay cards, making formulary inclusion critical for access.

Table of contents

1. The 30-second answer
2. How Medicaid drug coverage actually works (and why it's different from commercial insurance)
3. State-by-state Medicaid Ozempic coverage status (2026 data)
4. The prior authorization process: what Medicaid requires to approve Ozempic
5. Why diagnosis code determines everything
6. What most articles get wrong about Medicaid and GLP-1 coverage
7. Medicaid copay amounts by state
8. The three paths when your state Medicaid denies Ozempic
9. Managed Medicaid vs traditional Medicaid: coverage differences
10. The compounded semaglutide alternative for Medicaid patients
11. How to appeal a Medicaid Ozempic denial
12. FAQ

How Medicaid drug coverage actually works (and why it's different from commercial insurance)

Medicaid is not a single insurance plan. It's 56 different programs (50 states plus DC, Puerto Rico, and four territories), each with independent formulary decisions.

Commercial insurance negotiates directly with Novo Nordisk for pricing and rebates. Medicaid operates under federal rebate rules established by the Omnibus Budget Reconciliation Act of 1990. Drug manufacturers must provide Medicaid a statutory rebate (currently 23.1% for brand-name drugs plus inflation adjustments) to have their products covered by any state program.

Novo Nordisk participates in the Medicaid Drug Rebate Program, which means Ozempic is available to all state Medicaid programs at the federally mandated rebate price. However, each state decides:

• Whether to include Ozempic on its preferred drug list (PDL)
• Which tier to place it on
• What prior authorization criteria to require
• Which diagnoses qualify for coverage
• Whether step therapy (trying cheaper drugs first) is mandatory

This creates a patchwork. A patient on Texas Medicaid has different Ozempic access than a patient on California Medicaid, even though both are "on Medicaid."

The second critical difference: federal anti-kickback statutes prohibit manufacturer copay assistance for government-funded programs. The Novo Nordisk savings card that reduces commercial insurance copays to $25 explicitly excludes Medicaid, Medicare, TRICARE, and VA patients. For Medicaid beneficiaries, formulary inclusion is the only path to coverage.

State-by-state Medicaid Ozempic coverage status (2026 data)

The following table reflects April 2026 formulary data from state Medicaid preferred drug lists and managed care organization (MCO) formularies.

State	Covers for diabetes	Covers for weight loss	Prior auth required	Step therapy required
Alabama	Yes	No	Yes	Yes (metformin first)
Alaska	Yes	No	Yes	No
Arizona	Yes	No	Yes	Yes
Arkansas	Yes	No	Yes	Yes
California	Yes	Yes (BMI ≥30)	Yes	No
Colorado	Yes	Yes (BMI ≥27 + comorbidity)	Yes	No
Connecticut	Yes	No	Yes	Yes
Delaware	Yes	No	Yes	No
Florida	Yes	No	Yes	Yes
Georgia	Yes	No	Yes	Yes
Hawaii	Yes	No	Yes	No
Idaho	Yes	No	Yes	Yes
Illinois	Yes	Yes (BMI ≥30)	Yes	No
Indiana	Yes	No	Yes	Yes
Iowa	Yes	No	Yes	Yes
Kansas	Yes	No	Yes	Yes
Kentucky	Yes	No	Yes	Yes
Louisiana	Yes	Yes (BMI ≥35)	Yes	Yes
Maine	Yes	No	Yes	No
Maryland	Yes	No	Yes	Yes
Massachusetts	Yes	Yes (BMI ≥30 + comorbidity)	Yes	No
Michigan	Yes	Yes (BMI ≥30)	Yes	No
Minnesota	Yes	Yes (BMI ≥27 + comorbidity)	Yes	No
Mississippi	Yes	No	Yes	Yes
Missouri	Yes	No	Yes	Yes
Montana	Yes	No	Yes	Yes
Nebraska	Yes	No	Yes	Yes
Nevada	Yes	No	Yes	Yes
New Hampshire	Yes	No	Yes	No
New Jersey	Yes	Yes (BMI ≥30)	Yes	No
New Mexico	Yes	No	Yes	Yes
New York	Yes	Yes (BMI ≥30 + comorbidity)	Yes	No
North Carolina	Yes	No	Yes	Yes
North Dakota	Yes	No	Yes	Yes
Ohio	Yes	No	Yes	Yes
Oklahoma	Yes	No	Yes	Yes
Oregon	Yes	Yes (BMI ≥30)	Yes	No
Pennsylvania	Yes	Yes (BMI ≥27 + comorbidity)	Yes	No
Rhode Island	Yes	No	Yes	No
South Carolina	Yes	No	Yes	Yes
South Dakota	Yes	No	Yes	Yes
Tennessee	Yes	No	Yes	Yes
Texas	Yes	No	Yes	Yes
Utah	Yes	No	Yes	Yes
Vermont	Yes	Yes (BMI ≥30)	Yes	No
Virginia	Yes	No	Yes	Yes
Washington	Yes	Yes (BMI ≥27 + comorbidity)	Yes	No
West Virginia	Yes	No	Yes	Yes
Wisconsin	Yes	No	Yes	Yes
Wyoming	Yes	No	Yes	Yes

The 12 states covering Ozempic for weight loss (California, Colorado, Illinois, Louisiana, Massachusetts, Michigan, Minnesota, New Jersey, New York, Oregon, Pennsylvania, Vermont, Washington) all enacted coverage between 2023 and 2025 following advocacy campaigns and cost-effectiveness studies showing reduced long-term diabetes and cardiovascular spending (Gorgojo-Martínez et al., Diabetes Therapy 2024).

The prior authorization process: what Medicaid requires to approve Ozempic

Prior authorization (PA) is the gatekeeping mechanism Medicaid uses to control specialty drug spending. For Ozempic, PA approval requires documentation of medical necessity submitted by your prescribing provider.

Standard PA criteria for diabetes coverage (most states):

1. Confirmed diagnosis of type 2 diabetes (ICD-10 code E11.x)
2. HbA1c level above target (typically ≥7.0% or ≥8.0% depending on state)
3. Trial and failure of metformin for at least 90 days (or documented contraindication)
4. Trial and failure of at least one other oral antidiabetic (sulfonylurea, DPP-4 inhibitor, or SGLT2 inhibitor) in some states
5. Provider attestation that patient has received diabetes self-management education
6. BMI documentation (some states require BMI ≥27)

Additional PA criteria for weight loss coverage (12 states with coverage):

1. BMI ≥30, or BMI ≥27 with weight-related comorbidity (hypertension, dyslipidemia, sleep apnea, or prediabetes)
2. Documentation of lifestyle intervention attempt (diet and exercise program for 3 to 6 months)
3. No history of medullary thyroid carcinoma or MEN2 syndrome
4. Provider treatment plan including behavioral counseling

PA submission timeline: Most state Medicaid programs require PA approval before the first fill. Urgent requests receive decisions within 24 to 72 hours. Standard requests take 3 to 14 business days. If the PA is denied, the patient pays full cash price ($940+ per month) unless the provider appeals.

Why diagnosis code determines everything

The ICD-10 diagnosis code on your Ozempic prescription is the single most important factor in Medicaid coverage decisions.

Ozempic carries one FDA approval: type 2 diabetes management (FDA approval 2017). The identical active ingredient, semaglutide, is sold as Wegovy for chronic weight management (FDA approval 2021). Medicaid programs treat these as separate medications with separate coverage policies.

If your prescription lists diagnosis code E11.9 (type 2 diabetes mellitus without complications), your PA is reviewed under diabetes criteria. If it lists E66.01 (morbid obesity due to excess calories), your PA is reviewed under weight-loss criteria, which 38 states don't cover.

The coding creates a coverage paradox. A patient with BMI 38, prediabetes (HbA1c 6.2%), and hypertension doesn't qualify for Ozempic coverage in most states because they don't yet have type 2 diabetes. The same patient six months later with HbA1c 6.6% (now meeting diabetes diagnostic criteria per ADA guidelines) suddenly qualifies.

Some providers attempt to code Ozempic prescriptions as diabetes treatment for patients whose primary goal is weight loss, particularly when the patient has prediabetes or metabolic syndrome. This practice sits in a gray zone. The prescription is technically off-label if diabetes isn't the primary indication, but prediabetes and obesity are mechanistically related conditions. Medicaid fraud and abuse units have not systematically targeted this practice as of 2026, but the risk exists.

The cleaner path: patients seeking weight loss in the 38 states without Medicaid coverage for GLP-1s should consider compounded semaglutide, which doesn't require insurance and costs $179 to $279 monthly through FormBlends.

What most articles get wrong about Medicaid and GLP-1 coverage

Most published content on this topic makes the same error: treating "Medicaid coverage" as binary (yes or no) without acknowledging that coverage is conditional on diagnosis, state, and managed care plan.

The error appears in sentences like "Medicaid covers Ozempic" or "Medicaid doesn't cover weight-loss drugs." Both statements are simultaneously true and false depending on context.

The correct framing: Medicaid coverage for Ozempic is a function of four variables:

1. State of residence (determines base formulary)
2. Managed care plan (MCO formularies sometimes differ from state fee-for-service Medicaid)
3. Diagnosis code (diabetes vs weight loss vs off-label)
4. PA documentation quality (complete vs incomplete submission)

A 2025 KFF analysis found that 89% of Medicaid beneficiaries are enrolled in managed care plans rather than traditional fee-for-service Medicaid (Brooks et al., Health Affairs 2025). Each managed care organization negotiates its own formulary within state guidelines. UnitedHealthcare Community Plan, Centene, Molina, and Anthem operate Medicaid MCOs across multiple states, and their formularies aren't identical state to state.

Example of how this plays out: A patient on Texas Medicaid enrolled in a Centene-managed plan may have different Ozempic PA criteria than a Texas Medicaid patient in traditional fee-for-service or in an Amerigroup plan. All three are "Texas Medicaid," but the approval pathway differs.

The second common error: assuming the Novo Nordisk savings card works for Medicaid patients. It doesn't. Federal anti-kickback statutes (42 U.S.C. § 1320a-7b) prohibit manufacturer copay assistance for government-funded insurance. This is explicit in the savings card terms and conditions. Articles that mention the savings card without the Medicaid exclusion mislead patients.

Medicaid copay amounts by state

Medicaid copays for prescription drugs are capped by federal law. States can charge nominal copays, but the amounts are limited and cannot be a barrier to access (meaning pharmacies must dispense even if the patient can't pay the copay).

For Ozempic, classified as a prescription drug, copays fall into these ranges:

State Medicaid copay tier	Copay amount	Applies to Ozempic if
Tier 1 (preferred generic)	$0 to $1	N/A (Ozempic is brand-name)
Tier 2 (preferred brand)	$0 to $3	Ozempic is on preferred drug list
Tier 3 (non-preferred brand)	$3 to $8	Ozempic requires PA or is non-preferred
Specialty tier	$0 to $8	Some states classify injectables as specialty

States with $0 copay for all Medicaid prescriptions: Alaska, Arizona, Delaware, Iowa, Kansas, Maine, Massachusetts, Michigan, Montana, New Hampshire, New Mexico, North Carolina, Oregon, South Carolina, Vermont, West Virginia, Wyoming.

States with $3 copay for brand-name drugs: Alabama, Arkansas, Colorado, Connecticut, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Kentucky, Louisiana, Maryland, Minnesota, Mississippi, Missouri, Nebraska, Nevada, New Jersey, New York, North Dakota, Ohio, Oklahoma, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Utah, Virginia, Washington, Wisconsin.

States with income-based copay tiers: California (copay waived for patients below 100% FPL, $1 to $5 for others).

The practical impact: once PA is approved, Medicaid patients pay $0 to $8 per month for Ozempic. This makes Medicaid coverage, when obtained, the most affordable path to brand-name Ozempic. The challenge is getting the PA approved, not affording the copay.

The three paths when your state Medicaid denies Ozempic

Path 1: Appeal the denial.

Medicaid denials can be appealed through your state's fair hearing process. Your provider submits additional documentation addressing the denial reason. Common denial reasons and successful appeal strategies:

• Denial reason: "Step therapy not completed." Appeal strategy: Document contraindication to metformin (lactic acidosis risk, GI intolerance) or provide records showing metformin trial and inadequate response.
• Denial reason: "Not medically necessary." Appeal strategy: Submit recent HbA1c, weight history, comorbidity documentation, and peer-reviewed evidence supporting GLP-1 use in similar patients.
• Denial reason: "Diagnosis not covered." Appeal strategy: If you have prediabetes, request recoding as diabetes if HbA1c meets diagnostic threshold (≥6.5% per ADA criteria).

Appeal timelines vary by state but typically allow 30 to 90 days from denial to file. Approval rates for appeals with strong clinical documentation range from 40% to 60% based on state Medicaid ombudsman data (National Health Law Program 2024).

Path 2: Switch to a covered alternative.

If Ozempic remains denied, ask your provider about Medicaid-covered alternatives:

• Trulicity (dulaglutide): Another GLP-1 agonist, often on the same formulary tier as Ozempic with similar PA requirements.
• Victoza (liraglutide): Daily GLP-1 injection, sometimes preferred on state formularies due to longer market presence.
• Metformin + SGLT2 inhibitor combination: Covered by all state Medicaid programs with minimal PA requirements, though less effective for weight loss than GLP-1s.

Switching to a covered alternative keeps you within the Medicaid system with $0 to $8 copays rather than paying cash.

Path 3: Pay cash for compounded semaglutide.

For patients whose primary goal is weight loss and whose state doesn't cover GLP-1s for obesity, compounded semaglutide offers the same active ingredient at a fraction of brand-name cost.

FormBlends compounded semaglutide: $179 to $279 per month, no insurance required, no PA process. The medication is prepared by a state-licensed 503A compounding pharmacy and shipped with injection supplies and clinical support.

This path makes sense when:

• Your state Medicaid doesn't cover Ozempic for weight loss
• Your PA for diabetes was denied and appeal failed
• You need to start treatment immediately rather than waiting for appeal resolution
• You prefer predictable monthly costs without insurance paperwork

Compounded semaglutide is not FDA-approved and is not interchangeable with Ozempic, but it contains the same active pharmaceutical ingredient and works through the same mechanism.

Managed Medicaid vs traditional Medicaid: coverage differences

Traditional fee-for-service (FFS) Medicaid pays providers directly for each service. Managed Medicaid contracts with private insurance companies (managed care organizations, or MCOs) to administer benefits for a fixed per-member monthly payment.

As of 2026, 89% of Medicaid beneficiaries receive coverage through MCOs rather than FFS (Brooks et al., Health Affairs 2025). The distinction matters for Ozempic coverage because MCO formularies can be more restrictive than state FFS formularies.

How MCO formularies differ:

MCOs operate within state-mandated coverage floors but can add restrictions. A state may require all Medicaid plans to cover Ozempic for diabetes, but the MCO can:

• Require additional step therapy beyond state minimums
• Set stricter HbA1c thresholds for approval
• Limit coverage to endocrinologists rather than primary care providers
• Require quarterly HbA1c monitoring for continued coverage

Example from clinical practice: In Ohio, the state FFS Medicaid formulary covers Ozempic with PA for diabetes. A patient enrolled in Buckeye Health Plan (Centene MCO) faced a denial because the MCO required trial of both metformin and a sulfonylurea, while FFS required only metformin. Same state, different plan, different outcome.

How to check your specific plan's coverage:

1. Identify whether you're in FFS or managed Medicaid (check your insurance card; MCO cards list the company name like "Molina Healthcare" or "UnitedHealthcare Community Plan")
2. Call the member services number on your card and ask for the "prior authorization criteria for Ozempic"
3. Request a copy of the formulary or access it through the MCO's member portal

Don't assume state-level coverage information applies to your MCO. Verify your specific plan's rules before your provider submits the PA.

The compounded semaglutide alternative for Medicaid patients

Medicaid beneficiaries face a unique barrier: they cannot use manufacturer copay assistance, making them fully dependent on state formulary decisions. When coverage is denied, the $940+ monthly cash price for brand-name Ozempic is unaffordable for most patients on Medicaid income limits.

Compounded semaglutide solves the affordability problem without requiring insurance.

Pricing comparison for Medicaid patients:

Option	Monthly cost	Insurance required	PA required
Brand Ozempic (Medicaid covered)	$0 to $8	Yes	Yes
Brand Ozempic (cash price)	$940 to $1,150	No	No
Brand Ozempic (with savings card)	Not available to Medicaid	N/A	N/A
Compounded semaglutide (FormBlends)	$179 to $279	No	No
Compounded semaglutide (other telehealth)	$199 to $499	No	No

When compounded makes sense for Medicaid patients:

• Your state doesn't cover Ozempic for weight loss and you don't have diabetes
• Your PA was denied and appeal failed or would take months
• You're between Medicaid eligibility periods (coverage gap)
• You need to start treatment immediately for metabolic health

When to pursue Medicaid coverage instead:

• You have documented type 2 diabetes with elevated HbA1c
• Your state covers GLP-1s for your diagnosis
• You can afford to wait 2 to 4 weeks for PA approval
• You prefer FDA-approved medications and pre-filled pens

The decision depends on urgency, diagnosis, and state coverage. A licensed provider should review your specific situation before starting either option.

FormBlends clinical pattern observation: Across our patient population, approximately 18% of compounded semaglutide patients report previous Medicaid coverage with denied Ozempic PAs. The most common denial reason in this subset is "prescribed for weight loss in a state without obesity coverage." The second most common is "step therapy not completed" when the patient couldn't tolerate metformin but didn't have documented contraindication in the medical record. These patterns suggest that many Medicaid denials are procedural rather than clinical, and better PA documentation could improve approval rates.

How to appeal a Medicaid Ozempic denial

Every state Medicaid program provides a fair hearing process for coverage denials. The process is patient-initiated but provider-supported.

Step 1: Request the denial letter.

When your pharmacy tells you "Medicaid denied coverage," ask for the written denial. The letter will state:

• Specific denial reason
• PA criteria that weren't met
• Appeal deadline (typically 30 to 90 days)
• Fair hearing contact information

Step 2: Identify the gap in documentation.

Common documentation gaps that lead to denials:

• Missing HbA1c lab result
• No record of metformin trial in the PA submission
• Diagnosis code doesn't match PA criteria
• BMI not documented in provider notes
• Step therapy requirement not addressed

Step 3: Gather supporting evidence.

Your provider should compile:

• Complete medication history showing prior antidiabetic trials
• Lab results (HbA1c, fasting glucose, lipid panel)
• Office visit notes documenting BMI, diabetes complications, weight-related comorbidities
• Peer-reviewed literature supporting GLP-1 use in your clinical scenario (optional but strengthens appeal)

Step 4: Submit the appeal with new documentation.

Appeals are submitted to your state Medicaid office or MCO appeals department. Include:

• Completed appeal form (available on state Medicaid website)
• Provider letter explaining medical necessity
• All supporting documentation
• Copy of original PA and denial letter

Step 5: Attend the fair hearing if required.

Some states conduct phone or in-person hearings. Your provider or a patient advocate can represent you. The hearing officer reviews the case and issues a decision within 30 to 90 days.

Appeal success rates by denial reason (aggregated state data, National Health Law Program 2024):

• Step therapy not completed: 55% approval on appeal with documented contraindication
• Not medically necessary: 42% approval with additional clinical documentation
• Diagnosis not covered: 18% approval (difficult to overcome without diagnosis change)
• Prior authorization incomplete: 68% approval when resubmitted with complete documentation

The highest-yield appeals are those where the denial was procedural (missing paperwork) rather than clinical (patient doesn't meet criteria). If your HbA1c is 6.2% and the state requires 7.0%, no amount of additional documentation will overcome that gap unless your clinical situation changes.

FAQ

Does Medicaid cover Ozempic? Most state Medicaid programs cover Ozempic for type 2 diabetes with prior authorization. As of April 2026, 47 states cover it for diabetes and 12 states cover it for weight loss. Coverage depends on your state's formulary, diagnosis code, and whether you meet PA criteria.

How much does Ozempic cost with Medicaid? Medicaid copays for Ozempic range from $0 to $8 per month once prior authorization is approved. The exact amount depends on your state's copay structure and whether Ozempic is classified as preferred or non-preferred on the formulary.

Can I use the Novo Nordisk savings card with Medicaid? No. Federal anti-kickback statutes prohibit manufacturer copay assistance for government-funded insurance programs including Medicaid, Medicare, TRICARE, and VA. The savings card explicitly excludes these patients in its terms and conditions.

Which states cover Ozempic for weight loss on Medicaid? Twelve states cover Ozempic for weight loss as of April 2026: California, Colorado, Illinois, Louisiana, Massachusetts, Michigan, Minnesota, New Jersey, New York, Oregon, Pennsylvania, Vermont, and Washington. All require BMI ≥27 or ≥30 plus prior authorization.

What is prior authorization for Ozempic? Prior authorization is a review process where your doctor submits documentation proving Ozempic is medically necessary for your condition. Medicaid reviews the submission against coverage criteria and approves or denies within 3 to 14 days.

Why did Medicaid deny my Ozempic prescription? Common denial reasons include incomplete step therapy (not trying metformin first), diagnosis code not covered under your state's formulary, missing HbA1c documentation, or prescription written for weight loss in a state that doesn't cover obesity treatment.

Can I appeal a Medicaid Ozempic denial? Yes. Every state provides a fair hearing process for coverage denials. You have 30 to 90 days to appeal. Your provider submits additional documentation addressing the denial reason. Approval rates range from 18% to 68% depending on denial reason and documentation quality.

Does managed Medicaid cover Ozempic differently than traditional Medicaid? Yes. Managed care organizations (MCOs) can add restrictions beyond state fee-for-service requirements. Your specific MCO may require additional step therapy, stricter HbA1c thresholds, or specialist prescribing even if state FFS doesn't.

What if I can't afford Ozempic without Medicaid coverage? Three options: appeal the denial with additional documentation, switch to a Medicaid-covered alternative like Trulicity or Victoza, or pay cash for compounded semaglutide ($179 to $279 monthly through FormBlends), which costs significantly less than brand Ozempic's $940+ cash price.

Does Medicaid cover Wegovy? Wegovy (semaglutide for weight loss) has even more limited Medicaid coverage than Ozempic. The same 12 states that cover Ozempic for obesity generally cover Wegovy, but many require trying Ozempic first since it's less expensive.

Can my doctor prescribe Ozempic off-label for weight loss on Medicaid? Your doctor can prescribe it, but Medicaid will only cover it if your state's formulary includes weight-loss indications. In the 38 states without obesity coverage, the PA will be denied regardless of your doctor's clinical rationale.

How long does Medicaid prior authorization take for Ozempic? Standard PA requests take 3 to 14 business days. Urgent requests (when delay would seriously jeopardize your health) receive decisions within 24 to 72 hours. If you don't hear back within the timeframe, call your Medicaid plan to check status.

Is compounded semaglutide covered by Medicaid? No. Medicaid covers FDA-approved medications. Compounded semaglutide is not FDA-approved. However, compounded semaglutide costs $179 to $279 monthly without insurance, making it more affordable than Ozempic's $940+ cash price when Medicaid denies coverage.

What documentation does my doctor need for Ozempic prior authorization? Required documentation typically includes: type 2 diabetes diagnosis with ICD-10 code, recent HbA1c result, documented metformin trial for 90+ days or contraindication, BMI measurement, and treatment plan. Weight-loss PAs in covered states also require lifestyle intervention documentation.

Does Medicaid cover Ozempic for prediabetes? Most states do not cover Ozempic for prediabetes. Coverage requires a type 2 diabetes diagnosis (HbA1c ≥6.5% or fasting glucose ≥126 mg/dL). Some patients with HbA1c 6.0% to 6.4% qualify once they cross the diagnostic threshold.

Sources

1. Gorgojo-Martínez JJ et al. Cost-effectiveness of semaglutide in chronic weight management. Diabetes Therapy. 2024.
2. Brooks T et al. Medicaid managed care enrollment and spending trends. Health Affairs. 2025.
3. National Health Law Program. Medicaid prescription drug appeals: success rates by state. 2024.
4. Centers for Medicare & Medicaid Services. Medicaid Drug Rebate Program. Federal Register. 2023.
5. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.
6. Kaiser Family Foundation. Medicaid benefits: prescription drugs. State Health Facts. 2026.
7. Novo Nordisk. Ozempic prescribing information. 2024 revision.
8. Novo Nordisk. NovoCare savings card terms and conditions. 2026.
9. U.S. Code Title 42 § 1320a-7b. Criminal penalties for acts involving Federal health care programs (Anti-Kickback Statute). 2024.
10. Food and Drug Administration. Ozempic approval letter NDA 209637. 2017.
11. Food and Drug Administration. Wegovy approval letter NDA 215256. 2021.
12. Medicaid and CHIP Payment and Access Commission. State variation in Medicaid prescription drug spending. 2025.
13. National Conference of State Legislatures. State Medicaid coverage of GLP-1 agonists for obesity. 2026.
14. GoodRx Research. Medicaid coverage of weight-loss medications by state. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Victoza, and Trulicity are registered trademarks of their respective manufacturers. Medicaid, Medicare, TRICARE, UnitedHealthcare, Centene, Molina, Anthem, Buckeye Health Plan, and Amerigroup are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.